Estrella Immunopharma
ESLA
15 hedge funds and large institutions have $1.56M invested in Estrella Immunopharma in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 2 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
77% more capital invested
Capital invested by funds: $879K → $1.56M (+$680K)
15% more funds holding
Funds holding: 13 → 15 (+2)
0.64% more ownership
Funds ownership: 2.01% → 2.65% (+0.64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$212K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$106K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$74K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
+$52.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$89.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.62K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$1 |
ESLA Hedge Fund Activity: Q4 2025 in Review
15 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2025, worth a combined $1.56M — up 77% from $879K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ESLA positions and 2 closed out — a net gain of 4 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $212K. The largest seller was UBS Group, cutting an estimated $89.3K.
- 15 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2025, up from 13 in Q3 2025.
- Funds reported $1.56M of Estrella Immunopharma stock for Q4 2025, up 77% quarter-over-quarter.
- 6 funds opened new Estrella Immunopharma positions in Q4 2025 and 2 closed out, a net change of +4 holders.
- The largest Estrella Immunopharma buyer in Q4 2025 was Renaissance Technologies, an estimated $212K added.
- The largest Estrella Immunopharma seller in Q4 2025 was UBS Group, an estimated $89.3K sold.
Based on aggregated 13F filings for Q4 2025.